» Articles » PMID: 28400549

Associations of Prostate-Specific Antigen, Prostate Carcinoma Tissue Gleason Score, and Androgen Receptor Expression with Bone Metastasis in Patients with Prostate Carcinoma

Overview
Journal Med Sci Monit
Date 2017 Apr 13
PMID 28400549
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND Prostate carcinoma (PCa) is often not diagnosed until advanced disease with bone metastasis. Predictive factors for bone metastasis are required to improve patient outcomes. The study aimed to analyze the factors associated with bone metastases in newly diagnosed patients with PCa. MATERIAL AND METHODS This was a retrospective study of 80 patients newly diagnosed with PCa by pathological examination between January 2012 and December 2014. Bone metastases were diagnosed by positron emission computed tomography. Clinical data, serological laboratory results, and pathological examination results were collected. RESULTS Among the 80 patients, 45 (56%) had bone metastases. Age, serum alkaline phosphatase, prostate-specific antigen (PSA), erythrocyte sedimentation rate, PCa tissue Gleason score, androgen receptor (AR) expression, and Ki-67 expression were higher in patients with bone metastasis compared with those without (all P<0.05). Multivariate logistic regression showed that PSA (OR: 1.005; 95%CI: 1.001-1.010; P=0.016), Gleason score (OR: 4.095; 95%CI: 1.592-10.529; P=0.003), and AR expression (OR: 14.023; 95%CI: 3.531-55.6981; P=0.005) were independently associated with bone metastases. Cut-off values for PSA, Gleason score, and AR expression were 67.1 ng/ml (sensitivity: 55.6%; specificity: 97.1%), 7.5 (sensitivity: 75.6%; specificity: 82.9%), and 2.5 (sensitivity: 84.0%; specificity: 91.4%), respectively. CONCLUSIONS PSA, Gleason score, and AR expression in PCa tissues were independently associated with PCa bone metastases. These results could help identifying patients with PCa at high risk of bone metastases.

Citing Articles

JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4.

Hu Y, Zhao Z, Xie Q, Li H, Zhang C, He X Theranostics. 2025; 15(4):1320-1337.

PMID: 39816691 PMC: 11729558. DOI: 10.7150/thno.104135.


Machine learning discrimination of Gleason scores below GG3 and above GG4 for HSPC patients diagnosis.

Zhu B, Dai L, Wang H, Zhang K, Zhang C, Wang Y Sci Rep. 2024; 14(1):25641.

PMID: 39465343 PMC: 11514210. DOI: 10.1038/s41598-024-77033-1.


The miRNAs 203a/210-3p/5001-5p regulate the androgen/androgen receptor/YAP-induced migration in prostate cancer cells.

Huo C, Kuo Y, Lin C, Shiah S, Li C, Huang S Cancer Med. 2024; 13(16):e70106.

PMID: 39149855 PMC: 11327718. DOI: 10.1002/cam4.70106.


Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.

Hong H, Liang D, Liu Q, Wu G, Sun R, Liu J Quant Imaging Med Surg. 2022; 12(3):1750-1761.

PMID: 35284288 PMC: 8899971. DOI: 10.21037/qims-21-365.


Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.

Miyashita H, Cruz C, Patel V Support Care Cancer. 2021; 30(2):981-984.

PMID: 34373957 DOI: 10.1007/s00520-021-06340-4.


References
1.
Baade P, Youlden D, Cramb S, Dunn J, Gardiner R . Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 2013; 1(2):47-58. PMC: 3814115. DOI: 10.12954/PI.12014. View

2.
Tanaka N, Fujimoto K, Shinkai T, Nakai Y, Kuwada M, Anai S . Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis. Jpn J Clin Oncol. 2011; 41(10):1209-13. DOI: 10.1093/jjco/hyr118. View

3.
Huxley R, Ansary-Mohaddam A, Huxley R, Barzi F, Lam T, Jamrozik K . The impact of modifiable risk factors on mortality from prostate cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev. 2007; 8(2):199-205. View

4.
Velonas V, Woo H, Dos Remedios C, Assinder S . Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14(6):11034-60. PMC: 3709717. DOI: 10.3390/ijms140611034. View

5.
Albertsen P, Hanley J, Barrows G, Penson D, Kowalczyk P, Sanders M . Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst. 2005; 97(17):1248-53. DOI: 10.1093/jnci/dji248. View